Samsung takes first step into biosimilars through Quintiles joint venture
This article was originally published in Scrip
Samsung is to set up a Won300 billion ($265 million) joint venture with Quintiles Transnational for the contract manufacture of biopharmaceuticals that will also eventually make biosimilar and original biologic products developed by the diversified South Korean conglomerate.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context